@article{cdb7610119e844c59967424e1118dc94,
title = "New twists in the AXL(e) of tumor progression",
abstract = "Patients with a mesenchymal subtype of ovarian cancer face a poor prognosis with limited treatment options to halt metastatic progression. In this issue of Science Signaling, Antony et al. found that the kinase AXL drives the mesenchymal gene signature and motility of ovarian tumor cells. AXL inhibitors may thus slow tumor progression in this subset of patients. 2016",
author = "Balazs Halmos and Haura, {Eric B.}",
note = "Funding Information: Work in the authors' laboratories is funded by the National Cancer Institute (CA202970 and CA181848) and the State of Florida (5BC07 to E.B.H.). B.H. currently receives clinical research funding from Mirati, AstraZeneca, Boehringer-Ingelheim, Merck, Novartis, Eli-Lilly, and Ariad Pharmaceuticals. Competing interests: E.B.H. currently receives research funding from Ignyta Pharmaceuticals related to AXL signaling inhibitors. B.H. currently receives research funding from Mirati Pharmaceuticals related to AXL signaling inhibitors. Publisher Copyright: {\textcopyright} The Authors, some rights reserved.",
year = "2016",
month = oct,
day = "4",
doi = "10.1126/scisignal.aai7619",
language = "English (US)",
volume = "9",
journal = "Science Signaling",
issn = "1945-0877",
publisher = "American Association for the Advancement of Science",
number = "448",
}
